Strategic Global Advisors LLC Has $1.50 Million Stake in Smith & Nephew plc (NYSE:SNN)
Strategic Global Advisors LLC boosted its holdings in shares of Smith & Nephew plc (NYSE:SNN) by 0.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,482 shares of the medical equipment provider’s stock after purchasing an additional 226 shares during the period. Strategic Global Advisors LLC’s holdings in Smith & Nephew were worth $1,501,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also modified their holdings of SNN. FMR LLC lifted its position in shares of Smith & Nephew by 640.8% during the first quarter. FMR LLC now owns 1,341,034 shares of the medical equipment provider’s stock worth $53,788,000 after purchasing an additional 1,160,015 shares in the last quarter. Prio Wealth Limited Partnership bought a new position in Smith & Nephew in the 2nd quarter valued at $25,658,000. Nuance Investments LLC boosted its position in Smith & Nephew by 29.0% in the 2nd quarter. Nuance Investments LLC now owns 1,531,811 shares of the medical equipment provider’s stock valued at $66,695,000 after buying an additional 344,052 shares during the last quarter. Iridian Asset Management LLC CT increased its stake in shares of Smith & Nephew by 13.5% in the 2nd quarter. Iridian Asset Management LLC CT now owns 2,639,567 shares of the medical equipment provider’s stock valued at $114,927,000 after buying an additional 313,374 shares during the period. Finally, Fiduciary Management Inc. WI increased its stake in shares of Smith & Nephew by 2.9% in the 2nd quarter. Fiduciary Management Inc. WI now owns 8,420,997 shares of the medical equipment provider’s stock valued at $366,650,000 after buying an additional 233,761 shares during the period. Hedge funds and other institutional investors own 8.80% of the company’s stock.
Several equities analysts have recently issued reports on the company. Zacks Investment Research raised Smith & Nephew from a “hold” rating to a “buy” rating and set a $49.00 price target on the stock in a research note on Tuesday, July 2nd. Berenberg Bank upgraded Smith & Nephew from a “hold” rating to a “buy” rating in a research report on Tuesday, July 23rd. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $27.50.
About Smith & Nephew
Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Recommended Story: How Do Front-End Loads Impact an Investment?
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.